Lincoln National Corp’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Lincoln National Corp’s Portfolio NYMX Stock Details NYMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-11,215	Closed	-$2.13K	–	1075
2023 Q2	$2.13K	Buy	+11,215	New	+$4.42K	﹤0.01%	1015
2022 Q3	–	Sell	-10,315	Closed	-$4K	–	909
2022 Q2	$4K	Hold	10,315	–	–	﹤0.01%	859
2022 Q1	$13K	Hold	10,315	–	–	﹤0.01%	907
2021 Q4	$13K	Buy	+10,315	New	+$16.5K	﹤0.01%	889
2020 Q1	–	Sell	-10,000	Closed	-$22K	–	685
2019 Q4	$22K	Buy	+10,000	New	+$19.7K	﹤0.01%	640

Other funds holding NYMX

DDC

DF Dent & Co Baltimore, Maryland $5.22B AUM 2.07% 1-Year Est. Return

FCFC

First Citizens Financial Corp Mason City, Iowa $239M AUM 26.56% 1-Year Est. Return

CAM

Cubic Asset Management Boston, Massachusetts $422M AUM 29.18% 1-Year Est. Return

ODIJL

One Day In July LLC Burlington, Vermont $1.44B AUM 17.18% 1-Year Est. Return

Lincoln National Corp's NYMX Position: Q3 2023 in Review

Lincoln National Corp sold out of Nymox Pharmaceutical Corp (NYMX) in Q3 2023, closing a stake of 11,215 shares — an estimated $2.13K sold.

Lincoln National Corp first reported a position in NYMX in Q4 2019 and held it in 5 quarters. The position peaked at $22K in Q4 2019. 5 funds tracked by Wall St. Rank hold NYMX as of Q3 2023.

Lincoln National Corp reported no remaining Nymox Pharmaceutical Corp position as of Q3 2023 after selling out during the quarter.
Lincoln National Corp sold 11,215 Nymox Pharmaceutical Corp shares in Q3 2023, an estimated $2.13K.
Lincoln National Corp first reported a position in Nymox Pharmaceutical Corp in Q4 2019 and held it in 5 quarters.
Lincoln National Corp's Nymox Pharmaceutical Corp position peaked at $22K in Q4 2019.
5 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q3 2023.

Based on Lincoln National Corp's 13F filing for Q3 2023, filed 6 Nov 2023.